|MDACC Study No:||2012-0171 (clinicaltrials.gov NCT No: NCT01539512)|
|Title:||A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and|
Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic
|Principal Investigator:||William G. Wierda|
|Study Description:||The goal of this clinical research study is to find out if adding idelalisib to |
treatment with rituximab is more effective in controlling CLL than treatment
with rituximab alone. The safety of this drug combination will also be
Rituximab is designed to attach to cancer cells and damage them, which may
cause the cells to die.
Idelalisib is designed to block some of the cell functions that cause CLL cells
to grow and survive.
A placebo is not a drug. It looks like the study drug but is not designed to
treat any disease or illness. It is designed to be compared with a study drug
to learn if the study drug has any real effect.